Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai
14 nov. 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai Lugano, Switzerland, November 14, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer...
Helsinn to co-host MF-CTCL satellite symposium alongside Recordati Rare Diseases at the EADV 2019 Congress GNW: European only
09 oct. 2019 05h00 HE
|
Helsinn Healthcare S.A.
Helsinn to co-host alongside Recordati Rare Diseases satellite symposium on MF-CTCL diagnosis optimization at European Academy of Dermatology and Venereology Congress 2019 Lugano, Switzerland,...
Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019
26 sept. 2019 08h54 HE
|
Helsinn Healthcare S.A.
Helsinn demonstrates commitment to MF CTCL with multiple scientific sessions at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical...
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019
26 sept. 2019 06h35 HE
|
Helsinn Healthcare S.A.
Helsinn announces abstract accepted for oral presentation at the EORTC Cutaneous Lymphoma Meeting 2019 Lugano, Switzerland, September 26, 2019 – Helsinn, the Swiss pharmaceutical group focused on...
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma
19 sept. 2019 04h00 HE
|
Helsinn Healthcare S.A.
Helsinn and Recordati Rare Diseases to announce satellite symposium on advances in Mycosis Fungoides-Cutaneous T cell Lymphoma (MF-CTCL) treatment at the 49th European Society for Dermatological...
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
02 sept. 2019 08h30 HE
|
Consilium Strategic Communications
Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America Lugano, Switzerland, São Paulo, Brazil, and Buenos Aires,...
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
31 juil. 2019 08h10 HE
|
Helsinn Healthcare S.A.
Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada DUBLIN and LUGANO, July 31, 2019 -- Endo International plc (NASDAQ: ENDP), and Helsinn, a Swiss...
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors
26 juin 2019 01h00 HE
|
Helsinn Healthcare S.A.
Helsinn appoints Giorgio Calderari, Group General Manager and Chief Operating Officer, to the Board of Directors Lugano, Switzerland, June 26, 2019: Helsinn, the Swiss pharmaceutical group focused on...
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology
07 juin 2019 03h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group supports two events with the International Society for Cutaneous Lymphomas (ISCL) at the 24th World Congress of Dermatology Cutaneous Lymphoma Meeting will update on latest developments...
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania
01 juin 2019 08h00 HE
|
Helsinn Healthcare S.A.
Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Dr. Allison Barz Leahy, MD, University of Pennsylvania ...